Asset Details
Do you wish to reserve the book?
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Do you wish to request the book?
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011
Overview
In this trial, daily oral sunitinib was associated with a median progression-free survival of 11.4 months, as compared with 5.5 months for placebo (hazard ratio, 0.42; 95% confidence interval, 0.26 to 0.67; P<0.001), in patients with advanced pancreatic neuroendocrine tumors.
Pancreatic neuroendocrine tumors are uncommon tumors arising from endocrine cells of the pancreas.
1
Surgery is the mainstay of treatment for resectable disease,
2
and therapy directed to the liver may have some palliative benefit for metastases that occur predominantly in the liver.
3
,
4
Somatostatin analogues relieve symptoms resulting from hormone hypersecretion in functioning tumors and may delay disease progression in selected patients.
5
–
7
Streptozocin alone or in combination with doxorubicin remains the only chemotherapeutic agent approved for the treatment of advanced pancreatic neuroendocrine tumors,
8
–
11
though the magnitude of benefit has been challenged.
12
,
13
Vascular endothelial growth factor (VEGF) is a . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Liver. Biliary tract. Portal circulation. Exocrine pancreas
/ Male
/ Neuroendocrine Tumors - drug therapy
/ Neuroendocrine Tumors - mortality
/ Pancreatic Neoplasms - drug therapy
/ Pancreatic Neoplasms - mortality
/ Protein Kinase Inhibitors - therapeutic use
/ Proteins
/ Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
/ Tumors
We currently cannot retrieve any items related to this title. Kindly check back at a later time.